为探究外周 TREM 2 与脑内阿尔茨海默病（AD）病理的关系，研究人员对 318 名中国老年人开展研究，检测血浆可溶性 TREM 2 （sTREM 2 ）等指标。结果发现 sTREM 2 与脑内 tau 积累呈负相关，该研究为 AD 治疗提供新思路。

Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline ...

编辑推荐：针对胃癌（GC）肿瘤微环境（TME）中免疫抑制机制不明的难题，山东第一医科大学附属省立医院团队通过单细胞RNA测序（scRNA-seq）和TCGA联合分析，首次揭示癌症相关成纤维细胞（CAFs）通过CXCL12-CXCR4信号轴增强TREM2 + 脂质相关巨噬细胞（LAMs）的免疫抑制 ...

“In addition to the existing evidence supporting TREM2 as a therapeutic target in AD, our continued interrogation of VG-3927 has demonstrated that by activating TREM2, we can engage the brain ...

Investing.com — 专注于神经退行性疾病的生物技术公司Vigil Neuroscience, Inc. (NASDAQ: VIGL )宣布其阿尔茨海默病 (AD)药物候选者VG-3927已进入二期临床试验阶段。根据 InvestingPro ...

unaddressed contributors of disease progression in AD. We are looking forward to progressing VG-3927 as the first and only oral, once-daily, clinical-stage small molecule TREM2 agonist into Phase ...

"We are thrilled to showcase our preclinical and Phase 1 data on VG-3927 at AD/PD™,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. "Today's two ...

It also binds proteins with a strong propensity for aggregation and accumulation, such as β-amyloid (Aβ). Indeed, TREM2 has been linked with neurological conditions such as Alzheimer’s disease (AD).

Vigil Neuroscience (VIGL) presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two ...